© 2018 by DWIB.org  | UK Charity no. 1127494

  • LinkedIn Social Icon
  • Facebook Social Icon
  • Twitter Social Icon
  • YouTube Social  Icon
NEW WA TEST FOR LEUKAEMIA WINS EUREKA PRIZE

A new medical invention that can detect genetic changes in leukaemia cells has been honoured at the 2018 Australian Museum Eureka Prizes ceremony.

Making chemotherapy kinder for childhood leukaemia

In this guest blog post, Dr Rosanna Jackson discusses what scientists are doing to make treatment kinder for children with acute lymphoblastic leukaemia (ALL).

AZ’s new leukaemia drug approved in the US

 

The FDA has approved a new cancer drug from AstraZeneca, the first medicine to treat a rare and life-threatening form of leukaemia to hit the market for 20 years. 

Biopharma’s acute myeloid leukaemia treatment gains orphan drug designation

Clinical-stage biopharmaceutical company, ASLAN Pharmaceuticals, has been granted orphan drug designation (ODD) for its treatment for acute myeloid leukaemia (AML) — ASLAN003 — by the US Food and Drug Administration (FDA).

New campaign puts spotlight on leukaemia

KEIGHLEY people are being urged to learn the symptoms of leukaemia. The plea has been issued by Leukaemia Care to coincide with Blood Cancer Awareness Month.

Drug to treat childhood leukaemia to be made available on the NHS 

 

A cutting-edge personalised treatment for a form of childhood leukaemia is to be made available on the NHS in the first deal of its kind in Europe.

I am Nigerian-German and urgently need an
African-European/ African-Caucasian stem cell donor who can help me to continue being there for my children, my husband and my friends.

Given the advanced nature of the disease,
every day, every hour, every minute counts!

Jazz Pharma’s leukaemia drug wins EU approval for AML

The European Commission has approved Jazz Pharmaceuticals' Vyxeos for the treatment of adults with newly diagnosed, therapy-related acute myeloid leukaemia or AML with myelodysplasia-related changes. 

Kymriah approved for acute lymphoblastic leukaemia

Novartis has announced that the European Commission (EC) has approved Kymriah® for the treatment of paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL).